Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 91.6%

Neg 0% Neu 0% Pos 91.6%

Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.